Twelve new game-changing drugs predicted to achieve
annual sales of >$1 billion by 2022, to the benefit of
millions of patients around the world.
PHILADELPHIA, March 22, 2018 /PRNewswire/—Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today the launch of its annual "Drugs to Watch" report. The analysis identified 12 new drugs forecast to achieve annual sales of $1 billion or more (ie, blockbuster status) by 2022 using the Cortellis database, which includes information gathered from diverse sources including drug pipelines, patents, clinical trials, chemistry, deals and company announcements. More blockbuster drugs have been predicted to launch in 2018 than in any other year since the Drugs to Watch report began in 2013.
The drugs forecasted to launch in 2018 cover a wide range of therapeutic areas—ie, type 2 diabetes, endometriosis, childhood epilepsy, hemophilia, HIV, migraine, opioid addiction and shingles. Noteworthy examples on this list include:
|
Drug & company |
Disease & Impact |
|
Aimovig
|
|
|
Biktarvy Gilead (USA) |
|
|
Ozempic |
|
|
|
Shingles: It's estimated around one in every four people will have at least one episode of shingles during their life.4 The only vaccine to make the list is GSK's Shingrix (Zoster vaccine recombinant, adjuvanted), which is set to become the market leading shingles vaccine. |
|
Sublocade |
|
2018 is also expected to see the launch of the first FDA-approved cannabidiol-based drug (Epidiolex)—potentially opening up a new market for cannabidiol-based medicines—and the first approved treatment option for men with castration-resistant prostate cancer (Erleada) whose cancer has not yet spread.
"Despite political and regulatory uncertainties in the USA and EU markets, the annual Drugs to Watch report 2018 shows that the pace of pharmaceutical innovation continues to accelerate," explained Mukhtar Ahmed, President, Life Sciences at Clarivate Analytics. "2018 is on track to see many new potential game-changing drugs come to market, which will benefit the lives of millions of patients around the world."
Data for this report were compiled from the Cortellis database, the premier source of life sciences competitive, clinical and regulatory intelligence and analytics which includes data gathered from diverse sources, including annual filings, drug pipelines, clinical trials, patents, chemistry, company announcements, deals and conferences.
ABOUT CORTELLIS
Cortellis delivers the unique insights needed to reduce risk and increase success across the drug development lifecycle from early discovery to commercialization and beyond. The Cortellis suite of solutions serves the needs of life science professionals with unmatched content, intelligent search, best-in class analytics and insightful visualization tools. For more information, visit clarivate.com/cortellis.
ABOUT THE DRUGS TO WATCH REPORT
The annual Drugs to Watch report was first published in 2013. Using data from Cortellis, the report aims to forecast which drug launches in a given year will achieve blockbuster status within five years of launch. Following an advanced analysis of this database, a shortlist of drugs is manually researched and evaluated by life-science experts at Clarivate Analytics, who review each drug in its individual context and assess clinical trial results, regulatory data, market data and regulatory designations for each drug.
The full report is available at: http://info.clarivate.com/drugstowatch2018
Follow us on Twitter: @Cortellis | #blockbusterdrugs2018
References
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606966/
2. http://www.who.int/hiv/en/
3. https://www.idf.org/about-diabetes/what-is-diabetes.html
4. https://www.nhs.uk/conditions/shingles/
5. https://www.ncbi.nlm.nih.gov/pubmed/24661272
|
Drug |
Disease |
2018 |
2019 |
2020 |
2021 |
2022 |
Company (HQ) | |
|
1 |
Hemlibra (emicizumab)*,†,|,¶,‡‡ |
Hemophilia A with factor |
496 |
1,457 |
2,356 |
3,362 |
4,002 |
Roche |
|
2 |
Biktarvy (tenofovir alafenamide + emtricitabine + bictegravir)**,¶, †† |
HIV infection |
896 |
2,282 |
3,387 |
4,296 |
3,716 |
Gilead (U.S.) |
|
3 |
Ozempic (semaglutide)* |
Type 2 diabetes
|
260 |
862 |
1,576 |
2,583 |
3,469 |
Novo Nordisk (Denmark) |
|
4 |
Erleada (apalutamide)¶,** |
Non-metastatic CRPC |
25 |
500 |
1,200 |
1,600 |
2,000 |
Johnson & Johnson (U.S.) |
|
5 |
Shingrix (Zoster vaccine recombinant, adjuvanted)§§ |
Shingles |
242 |
537 |
879 |
1,202 |
1,368 |
GlaxoSmithKline (UK) |
|
6 |
Patisiran§,|,¶,‡‡ |
Hereditary TTR amyloidosis |
83 |
373 |
726 |
1,104 |
1,212 |
Alnylam (U.S.)/Genzyme (U.S.) |
|
7 |
Epidiolex (plant-derived cannabidiol)‡|,¶,** |
Dravet syndrome and Lennox-Gastaut syndrome |
19 |
266 |
645 |
936 |
1,191 |
GW Pharmaceuticals (UK)
|
|
8 |
Aimovig (erenumab)*,‡‡ |
Migraine |
115 |
361 |
685 |
941 |
1,170 |
Amgen (U.S.)/Novartis (Switzerland) |
|
9 |
Lanadelumab*,†,|,¶,‡‡ |
Hereditary angioedema |
74 |
350 |
629 |
902 |
1,153 |
Shire (Ireland) |
|
10 |
Elagolix¶,**,‡‡ |
Endometriosis |
57 |
268 |
549 |
896 |
1,152 |
AbbVie (U.S.) |
|
11 |
Steglatro (ertugliflozin)** |
Type 2 diabetes
|
220 |
482 |
769 |
1,024 |
1,087 |
Pfizer (U.S.)/Merck (U.S.) |
|
12 |
Sublocade (once-monthly buprenorphine)‡,¶,** |
Opioid dependence |
121 |
308 |
439 |
634 |
1,072 |
Indivior (UK) |
Table: Analysis of 12 new drugs forecast to enter the market in 2018 and achieve blockbuster sales of over $1 billion by 2022
Data were obtained from the Cortellis Competitive Intelligence database, accessed March 05, 2018 (Source: Thomson Reuters I/B/E/S). Forecasts are in U.S.$ million. CRPC=castration-resistant prostate cancer. TTR=transthyretin*=biological drug. †=Breakthrough Therapy designation. ‡=Fast Track designation. §=RNA interference. |=Orphan Drug designation. ¶=Priority Review. **=small molecule. ††=novel integrase inhibitor. ‡‡=first-in-class. §§= vaccine.
SOURCE Clarivate Analytics
